Medpace (MEDP) Revenue & Revenue Breakdown
Medpace Revenue Highlights
Latest Revenue (Y)
$1.89B
Latest Revenue (Q)
$528.10M
Main Segment (Y)
Revenue Net
Medpace Revenue by Period
Medpace Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.89B | 29.17% |
| 2022-12-31 | $1.46B | 27.80% |
| 2021-12-31 | $1.14B | 23.38% |
| 2020-12-31 | $925.92M | 7.54% |
| 2019-12-31 | $860.97M | 22.19% |
| 2018-12-31 | $704.59M | 61.55% |
| 2017-12-31 | $436.15M | 3.46% |
| 2016-12-31 | $421.58M | 17.41% |
| 2015-12-31 | $359.06M | 31.58% |
| 2013-12-31 | $272.89M | - |
Medpace generated $1.89B in revenue during NA 2023, up 29.17% compared to the previous quarter, and up 267.65% compared to the same period a year ago.
Medpace Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $528.10M | 3.34% |
| 2024-03-31 | $511.04M | 2.54% |
| 2023-12-31 | $498.40M | 1.20% |
| 2023-09-30 | $492.50M | 6.86% |
| 2023-06-30 | $460.87M | 6.17% |
| 2023-03-31 | $434.07M | 10.14% |
| 2022-12-31 | $394.10M | 2.70% |
| 2022-09-30 | $383.74M | 9.26% |
| 2022-06-30 | $351.21M | 6.12% |
| 2022-03-31 | $330.95M | 7.26% |
| 2021-12-31 | $308.55M | 4.39% |
| 2021-09-30 | $295.57M | 6.21% |
| 2021-06-30 | $278.29M | 7.05% |
| 2021-03-31 | $259.96M | 0.11% |
| 2020-12-31 | $259.68M | 12.72% |
| 2020-09-30 | $230.37M | 12.38% |
| 2020-06-30 | $205.00M | -11.21% |
| 2020-03-31 | $230.88M | 0.43% |
| 2019-12-31 | $229.89M | 6.31% |
| 2019-09-30 | $216.24M | 1.00% |
| 2019-06-30 | $214.10M | 6.66% |
| 2019-03-31 | $200.74M | 4.49% |
| 2018-12-31 | $192.12M | 7.18% |
| 2018-09-30 | $179.25M | 5.35% |
| 2018-06-30 | $170.14M | 4.33% |
| 2018-03-31 | $163.08M | 44.72% |
| 2017-12-31 | $112.68M | 1.84% |
| 2017-09-30 | $110.64M | 4.17% |
| 2017-06-30 | $106.22M | -0.37% |
| 2017-03-31 | $106.61M | -1.51% |
| 2016-12-31 | $108.24M | 0.41% |
| 2016-09-30 | $107.80M | 1.74% |
| 2016-06-30 | $105.95M | 6.39% |
| 2016-03-31 | $99.59M | 3.69% |
| 2015-12-31 | $96.04M | 4.24% |
| 2015-09-30 | $92.13M | 4.87% |
| 2015-06-30 | $87.85M | 5.81% |
| 2015-03-31 | $83.03M | 6.55% |
| 2014-03-31 | $77.93M | - |
Medpace generated $528.10M in revenue during Q2 2024, up 3.34% compared to the previous quarter, and up 121.66% compared to the same period a year ago.
Medpace Revenue Breakdown
Medpace Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Revenue Net | $1.46B | $34.50M | $15.90M | $18.90M | $15.10M |
| Antiviral And Anti Infective | $118.03M | $110.98M | $86.39M | $76.74M | - |
| Other | $296.91M | $267.42M | $222.51M | $161.19M | - |
| Cardiology | $174.63M | $119.69M | $91.26M | $91.82M | - |
| Central Nervous System | $157.94M | $121.55M | $65.39M | $53.90M | - |
| Metabolic | $244.68M | $159.90M | $138.65M | $94.13M | - |
| Oncology | $467.80M | $362.85M | $256.77M | $189.03M | - |
| Reimbursed Out Of Pocket Revenue | - | - | - | - | - |
| Direct Revenue | - | - | - | - | - |
| Endocrine | - | - | - | - | $26.00M |
| Medical Devices | - | - | - | - | $11.77M |
Medpace's latest annual revenue breakdown by segment (product or service), as of Dec 22: Revenue Net (50.00%), Oncology (16.02%), Other (10.17%), Metabolic (8.38%), Cardiology (5.98%), Central Nervous System (5.41%), and Antiviral And Anti Infective (4.04%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiviral And Anti Infective | $39.20M | $44.03M | $45.55M | $36.01M | $32.87M | $29.69M | $31.45M | $25.58M | $31.32M | $26.93M | $27.03M | $26.19M | $30.82M | $27.24M | $22.99M | $25.15M | $19.56M | $24.24M | $22.66M | - |
| Other | $112.43M | $108.40M | $106.16M | $101.06M | $87.10M | $80.17M | $72.77M | $73.56M | $70.42M | $70.27M | $64.09M | $64.12M | $68.94M | $55.54M | $45.20M | $50.57M | $63.84M | $53.48M | $51.94M | - |
| Oncology | $162.95M | $155.20M | $149.33M | $147.09M | $141.95M | $124.21M | $122.83M | $115.54M | $105.21M | $95.74M | $94.72M | $93.25M | $79.14M | $68.63M | $65.63M | $69.21M | $70.61M | $65.53M | $64.62M | - |
| Metabolic | $106.30M | $103.64M | $103.12M | $87.86M | $86.84M | $77.49M | $63.48M | $55.60M | $48.12M | $47.13M | $42.13M | $38.14M | $32.49M | $29.62M | $30.21M | $36.08M | $36.36M | $34.92M | $31.49M | - |
| Central Nervous System | $46.52M | $44.14M | $43.99M | $37.73M | $38.70M | $37.13M | $43.42M | $38.91M | $38.49M | $35.33M | $32.85M | $28.55M | $24.81M | $21.75M | $19.22M | $23.98M | $17.05M | $16.33M | $16.79M | - |
| Cardiology | $60.70M | $55.64M | $44.36M | $51.13M | $46.62M | $45.41M | $49.80M | $42.03M | $37.40M | $33.15M | $34.74M | $28.04M | $23.76M | $27.59M | $21.75M | $25.90M | $22.47M | $21.73M | $22.14M | - |
| Revenue Net | - | - | $492.50M | $460.87M | $434.07M | $394.10M | $383.74M | $17.20M | $13.30K | $10.60M | $8.70M | $9.90M | $5.30M | $4.30M | $3.40M | $2.70M | $5.50M | $5.20M | - | - |
| Medical Devices | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.46M |
Medpace's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Oncology (30.86%), Other (21.29%), Metabolic (20.13%), Cardiology (11.49%), Central Nervous System (8.81%), and Antiviral And Anti Infective (7.42%).
Medpace Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IQV | IQVIA | $14.98B | $3.81B |
| LH | Laboratory Corporation of America | $12.16B | $3.22B |
| ICLR | ICON Public Limited Company | $8.12B | $2.09B |
| CRL | Charles River Laboratories | $4.13B | $1.03B |
| MTD | Mettler-Toledo | $3.79B | $946.75M |
| IDXX | IDEXX Laboratories | $3.66B | $1.00B |
| WAT | Waters | $2.96B | $708.53M |
| RVTY | Revvity | $2.75B | $691.68M |
| QGEN | Qiagen | $1.97B | $458.80M |
| MEDP | Medpace | $1.89B | $528.10M |
| NEOG | Neogen | $924.22M | $228.81M |
| TWST | Twist Bioscience | $245.11M | $81.46M |
MEDP Revenue FAQ
What is Medpace’s yearly revenue?
Medpace's yearly revenue for 2023 was $1.89B, representing an increase of 29.17% compared to 2022. The company's yearly revenue for 2022 was $1.46B, representing an increase of 27.80% compared to 2021. MEDP's yearly revenue for 2021 was $1.14B, representing an increase of 23.38% compared to 2020.
What is Medpace’s quarterly revenue?
Medpace's quarterly revenue for Q2 2024 was $528.1M, a 3.34% increase from the previous quarter (Q1 2024), and a 14.59% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $511.04M, a 2.54% increase from the previous quarter (Q4 2023), and a 17.73% increase year-over-year (Q1 2023). MEDP's quarterly revenue for Q4 2023 was $498.4M, a 1.20% increase from the previous quarter (Q3 2023), and a 26.47% increase year-over-year (Q4 2022).
What is Medpace’s revenue growth rate?
Medpace's revenue growth rate for the last 3 years (2021-2023) was 65.08%, and for the last 5 years (2019-2023) was 119.04%.
What are Medpace’s revenue streams?
Medpace's revenue streams in c 22 are Revenue Net, Antiviral And Anti Infective, Other, Cardiology, Central Nervous System, Metabolic, and Oncology. Revenue Net generated $1.46B in revenue, accounting 50.00% of the company's total revenue, up 4131.87% year-over-year. Antiviral And Anti Infective generated $118.03M in revenue, accounting 4.04% of the company's total revenue, up 6.36% year-over-year. Other generated $296.91M in revenue, accounting 10.17% of the company's total revenue, up 11.03% year-over-year. Cardiology generated $174.63M in revenue, accounting 5.98% of the company's total revenue, up 45.90% year-over-year. Central Nervous System generated $157.94M in revenue, accounting 5.41% of the company's total revenue, up 29.94% year-over-year. Metabolic generated $244.68M in revenue, accounting 8.38% of the company's total revenue, up 53.02% year-over-year. Oncology generated $467.8M in revenue, accounting 16.02% of the company's total revenue, up 28.92% year-over-year.
What is Medpace’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Medpace was Revenue Net. This segment made a revenue of $1.46B, representing 50.00% of the company's total revenue.